Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

About the trial

Sponsor

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Tested

Mirdametinib (MEK Inhibitor) (drug)

Dates

Started 2025-04-24; completion 2026-10-31

Results posted

Not yet

The purposes of this study are to determine: * The pharmacokinetics (the amount of study drug in your blood and how long it takes the body to get rid of it) of the study drug and its metabolites (substances produced as the body breaks down the study drug) in participants with moderate or severe liver function impairment compared to participants with normal liver function (also known as a healthy volunteer). Pharmacokinetics (or PK) is the study of how your body absorbs, breaks down, and removes a study drug. * How well the study drug is tolerated and any side effects that may occur in participants with moderate or severe liver function impairment compared to participants with normal liver…

From ClinicalTrials.gov, last updated 2026-10-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Springworks Therapeutics, Inc. reported $689,486 in research payments for this study in 2025 (11 payments).

Products named: Gomekli

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.